Blood Test Determines Esophageal Cancer Patient Treatment Options
By LabMedica International staff writers Posted on 21 Oct 2014 |
Image: A fluorescent proximity ligation assay of protein-protein interactions (Photo courtesy of Abnova).
A blood test that may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma has been introduced.
The blood test measures levels of two proteins found in the body, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1), indicate patients’ pathological response, and disease-free survival rates.
Scientists at the National Taiwan University Hospital (Taipei City, Taiwan) evaluated serum samples of 103 total patients with esophageal squamous cell carcinoma (ESCC) from 2004 to 2013. All patients received preoperative taxane-/5-fluorouracil-based chemotherapy (CCRT) and 40 gray (Gy) dose of radiation therapy prior to esophagectomy, the surgical removal of a part of the esophagus.
Serum samples were collected from patients before and within one month of completion of CCRT. The team used a proximity ligation assay (PLA) technique to screen for 15 serum biomarkers in 79 patients to evaluate the biomarkers’ association with pathological tumor regression on surgery and survival. The biomarkers significantly associated with pathological response (PathR) and survival rates were further analyzed by traditional enzyme-linked, immunosorbent assay (ELISA) to confirm initial biomarker findings by PLA in the total group of 103 patients.
The investigators found that patients with high VEGF-A were less likely to achieve complete tumor regression or a decrease in the size of a tumor or in the extent of cancer in the body, and that the survival rates were lower among patients who had high VEGF-A and high TGF-β1 levels before treatment. On ELISA, both pre- and post-CCRT VEGF-A levels were significantly correlated with PathR. Patients with pretreatment VEGF-A of less than 250 pg/mL showed a statistically significant pathologically complete response after CCRT (57.1%, or 20/35) compared to patients with VEGF-A of more than 250 pg/mL (26.5% or 18/68).
Jason Cheng, MD, the senior author of the study said, “Through the utilization of a specific blood test of serum biomarkers, we could potentially predict if a patient will have a favorable pathological response and outcome before radiotherapy. Treatment could be tailored for patients in order to achieve better outcomes and/or fewer side effects. Our study showed that the serum levels of VEGF-A and TGF-β1 were significant only before treatment. This would allow us to individualize the neoadjuvant treatment regimens based on the pretreatment serum levels of VEGF-A and TGF-β1.” The study was presented on September 14, 2014, at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting, held in San Francisco (CA, USA).
Related Links:
National Taiwan University Hospital
The blood test measures levels of two proteins found in the body, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1), indicate patients’ pathological response, and disease-free survival rates.
Scientists at the National Taiwan University Hospital (Taipei City, Taiwan) evaluated serum samples of 103 total patients with esophageal squamous cell carcinoma (ESCC) from 2004 to 2013. All patients received preoperative taxane-/5-fluorouracil-based chemotherapy (CCRT) and 40 gray (Gy) dose of radiation therapy prior to esophagectomy, the surgical removal of a part of the esophagus.
Serum samples were collected from patients before and within one month of completion of CCRT. The team used a proximity ligation assay (PLA) technique to screen for 15 serum biomarkers in 79 patients to evaluate the biomarkers’ association with pathological tumor regression on surgery and survival. The biomarkers significantly associated with pathological response (PathR) and survival rates were further analyzed by traditional enzyme-linked, immunosorbent assay (ELISA) to confirm initial biomarker findings by PLA in the total group of 103 patients.
The investigators found that patients with high VEGF-A were less likely to achieve complete tumor regression or a decrease in the size of a tumor or in the extent of cancer in the body, and that the survival rates were lower among patients who had high VEGF-A and high TGF-β1 levels before treatment. On ELISA, both pre- and post-CCRT VEGF-A levels were significantly correlated with PathR. Patients with pretreatment VEGF-A of less than 250 pg/mL showed a statistically significant pathologically complete response after CCRT (57.1%, or 20/35) compared to patients with VEGF-A of more than 250 pg/mL (26.5% or 18/68).
Jason Cheng, MD, the senior author of the study said, “Through the utilization of a specific blood test of serum biomarkers, we could potentially predict if a patient will have a favorable pathological response and outcome before radiotherapy. Treatment could be tailored for patients in order to achieve better outcomes and/or fewer side effects. Our study showed that the serum levels of VEGF-A and TGF-β1 were significant only before treatment. This would allow us to individualize the neoadjuvant treatment regimens based on the pretreatment serum levels of VEGF-A and TGF-β1.” The study was presented on September 14, 2014, at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting, held in San Francisco (CA, USA).
Related Links:
National Taiwan University Hospital
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities